| |
Turnkey pharmaceutical manufacturing facilities and a 75% property tax exemption make expanding your bioscience business to Puerto Rico easier than ever. It's not what's next, it's where. Puerto Rico.
|
|
Today’s Big NewsJan 28, 2025 |
|
Wednesday, February 12, 2025 | 10am ET / 7am PT If you are a company developing advanced therapies, don’t miss this webinar to learn about packaging innovations and aseptic filling solutions that meet the demands of emerging therapies and ensure product integrity, safety and efficiency.
|
|
| By Darren Incorvaia Just days after President Trump imposed broad restrictions on communications, meetings, travel and public appearances at the Department of Health and Human Services (HHS), the National Institutes of Health (NIH) is clarifying the extent of the freeze’s effect. |
|
|
|
By Zoey Becker The newly approved PI3K inhibitor helped patients live longer in the pivotal INAVO120 study, adding to the drug's previously reported progression-free survival win. |
By Conor Hale While Bridgefield will serve as the division’s new owner, its products will continue to carry the Philips name, through an international licensing deal set to span up to 15 years. |
By Gabrielle Masson A judge has sided with Aurion Biotech in a lawsuit brought by investor Alcon Research that aimed to stop the biotech's planned IPO. |
|
Wednesday, February 19, 2025 | 11am ET / 8am PT This webinar takes a deep dive into effective formulation strategies to overcome current solubility and bioavailability hurdles. Join us to explore the latest advancements in bioavailability enhancement technologies and critical factors for selecting the right formulation approach. Register now.
|
|
By Andrea Park To direct more attention toward the importance of regular breast cancer screenings, Novartis is taking to one of television’s biggest stages. |
By Kevin Dunleavy The FDA has cleared AstraZeneca and Daiichi Sankyo's Enhertu as the first HER2-directed treatment for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies. |
By Nick Paul Taylor BioAge Labs has given up on its lead obesity candidate. Weeks after stopping a trial in response to phase 2 data, the biotech has jettisoned the molecule and shifted its focus to a preclinical neuroinflammation prospect. |
By Fraiser Kansteiner Amgen reached a settlement with Celltrion, putting a bout of patent litigation to bed and allowing the South Korean company to launch its biosimilar versions of Amgen’s bone blockbusters Prolia and Xgeva as early as June 1. The settlement appears to mark the second of its kind following a similar accord between Amgen and Sandoz last spring. |
By James Waldron Two months after launching Pep2Tango, VC firm Versant Ventures is unveiling another obesity-focused biotech in the form of Helicore Biopharma. |
By Zoey Becker Under an executive order, the United States Agency for International Development is temporarily prohibited from delivering lifesaving drugs to its partner countries. |
By Gabrielle Masson Atalanta Therapeutics has bagged $97 million, money the biotech plans to use to launch clinical trials for its small interfering RNA (siRNA) candidates in epilepsy and Huntington’s disease. |
By Fraiser Kansteiner In a transaction that could ultimately work out to more than $1 billion in value, Lantheus is paying $250 million upfront to acquire clinical-stage radiopharma CDMO and drug discovery shop Evergreen Theragnostics. |
Fierce podcastsDon’t miss an episode |
| | This week on “The Top Line,” we break down the biggest stories out of JPM, from J&J’s blockbuster acquisition of Intra-Cellular Therapies to former First Lady Jill Biden’s appearance at Fierce JPM Week. |
|
|---|
|
|
|
Thursday, February 20, 2025 | 1pm ET / 10am PT ALS remains one of the most complex neurological diseases to understand and treat. Join industry experts to learn about the latest advancements in ALS research, with exclusive insights into the latest scientific progress shaping the future of ALS therapies. Register now.
|
|
| WhitepaperHow can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter, strategic consultants in the life sciences |
| |
|
